Galectin-9 Expression Defines Exhausted T Cells and Impaired Cytotoxic NK Cells in Patients with Virus-associated Solid Tumors

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2020 Dec 14

PMID 33310773

Citations 32

Authors

Isobel Okoye

Lai Xu

Melika Motamedi

Pallavi Parashar

John W Walker

Shokrollah Elahi

Affiliations

Soon will be listed here.

Abstract

Background: We have previously reported that the upregulation of galectin-9 (Gal-9) on CD4 and CD8 T cells in HIV patients was associated with impaired T cell effector functions. Gal-9 is a ligand for T cell immunoglobulin and mucin domain-3, and its expression on T cells in cancer has not been investigated. Therefore, we aimed to investigate the expression level and effects of Gal-9 on T cell functions in patients with virus-associated solid tumors (VASTs).

Methods: 40 patients with VASTs through a non-randomized and biomarker-driven phase II LATENT trial were investigated. Peripheral blood mononuclear cells and tumor biopsies were obtained and subjected to immunophenotyping. In this trial, the effects of oral valproate and avelumab (anti-PD-L1) was investigated in regards to the expression of Gal-9 on T cells.

Results: We report the upregulation of Gal-9 expression by peripheral and tumor-infiltrating CD4 and CD8 T lymphocytes in patients with VASTs. Our results indicate that Gal-9 expression is associated with dysfunctional T cell effector functions in the periphery and tumor microenvironment (TME). Coexpression of Gal-9 with PD-1 or T cell immunoglobulin and ITIM domain (TIGIT) exhibited a synergistic inhibitory effect and enhanced an exhausted T cell phenotype. Besides, responding patients to treatment had lower Gal-9 mRNA expression in the TME. Translocation of Gal-9 from the cytosol to the cell membrane of T cells following stimulation suggests persistent T cell receptor (TCR) stimulation as a potential contributing factor in Gal-9 upregulation in patients with VASTs. Moreover, partial colocalization of Gal-9 with CD3 on T cells likely impacts the initiation of signal transduction via TCR as shown by the upregulation of ZAP70 in Gal-9+ T cells. Also, we found an expansion of Gal-9+ but not TIGIT+ NK cells in patients with VASTs; however, dichotomous to TIGIT+ NK cells, Gal-9+ NK cells exhibited impaired cytotoxic molecules but higher Interferon gamma (IFN-γ) expression.

Conclusion: Our data indicate that higher Gal-9-expressing CD8 T cells were associated with poor prognosis following immunotherapy with anti-Programmed death-ligand 1 (PD-L1) (avelumab) in our patients' cohort. Therefore, for the very first time to our knowledge, we report Gal-9 as a novel marker of T cell exhaustion and the potential target of immunotherapy in patients with VASTs.

Citing Articles

It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma.

Knickmeier C, Noubissi Nzeteu G, Gibbs B, Hoogwater F, Nijkamp M, Bockhorn M Front Immunol. 2025; 16:1495907.

PMID: 39958335 PMC: 11825744. DOI: 10.3389/fimmu.2025.1495907.

Dichotomous effects of Galectin-9 in disease modulation in murine models of inflammatory bowel disease.

Tull S, Saviano A, Fatima A, Begum J, Mansour A, Marigliano N Biomed Pharmacother. 2025; 184:117902.

PMID: 39951917 PMC: 11870847. DOI: 10.1016/j.biopha.2025.117902.

Cell-associated galectin 9 interacts with cytotoxic T cells confers resistance to tumor killing in nasopharyngeal carcinoma through autophagy activation.

Kam N, Lau C, Lau J, Dai X, Liang Y, Lai S Cell Mol Immunol. 2025; 22(3):260-281.

PMID: 39910335 PMC: 11868493. DOI: 10.1038/s41423-024-01253-8.

PRDX2 induces tumor immune evasion by modulating the HDAC3-Galectin-9 axis in lung adenocarcinoma cells.

Dong Y, Cheng A, Zhou J, Guo J, Liu Y, Li X J Transl Med. 2025; 23(1):81.

PMID: 39825365 PMC: 11740609. DOI: 10.1186/s12967-024-05888-z.

Exploring the role of galectin-9 and artemin as biomarkers in long COVID with chronic fatigue syndrome: links to inflammation and cognitive function.

Elahi S, Rezaeifar M, Osman M, Shahbaz S Front Immunol. 2024; 15:1443363.

PMID: 39386210 PMC: 11461188. DOI: 10.3389/fimmu.2024.1443363.

References

Nishio A, Tatsumi T, Nawa T, Suda T, Yoshioka T, Onishi Y . CD14 monocyte-derived galectin-9 induces natural killer cell cytotoxicity in chronic hepatitis C. Hepatology. 2016; 65(1):18-31. DOI: 10.1002/hep.28847. View

Gooden M, de Bock G, Leffers N, Daemen T, Nijman H . The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011; 105(1):93-103. PMC: 3137407. DOI: 10.1038/bjc.2011.189. View

Wu C, Thalhamer T, Franca R, Xiao S, Wang C, Hotta C . Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity. 2014; 41(2):270-82. PMC: 4219323. DOI: 10.1016/j.immuni.2014.06.011. View

Melssen M, Slingluff Jr C . Vaccines targeting helper T cells for cancer immunotherapy. Curr Opin Immunol. 2017; 47:85-92. PMC: 5757837. DOI: 10.1016/j.coi.2017.07.004. View

Whiteside T . Immunobiology of head and neck cancer. Cancer Metastasis Rev. 2005; 24(1):95-105. DOI: 10.1007/s10555-005-5050-6. View

Bi S, Hong P, Lee B, Baum L . Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc Natl Acad Sci U S A. 2011; 108(26):10650-5. PMC: 3127870. DOI: 10.1073/pnas.1017954108. View

Elahi S, Dinges W, Lejarcegui N, Laing K, Collier A, Koelle D . Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med. 2011; 17(8):989-95. PMC: 3324980. DOI: 10.1038/nm.2422. View

Kindt N, Journe F, Ghanem G, Saussez S . Galectins and Carcinogenesis: Their Role in Head and Neck Carcinomas and Thyroid Carcinomas. Int J Mol Sci. 2017; 18(12). PMC: 5751344. DOI: 10.3390/ijms18122745. View

Heusschen R, Griffioen A, Thijssen V . Galectin-9 in tumor biology: a jack of multiple trades. Biochim Biophys Acta. 2013; 1836(1):177-85. DOI: 10.1016/j.bbcan.2013.04.006. View

10.

Ohue Y, Kurose K, Nozawa R, Isobe M, Nishio Y, Tanaka T . Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells. Cancer Immunol Res. 2016; 4(12):1049-1060. DOI: 10.1158/2326-6066.CIR-15-0266. View

11.

Borst J, Ahrends T, Babala N, Melief C, Kastenmuller W . CD4 T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018; 18(10):635-647. DOI: 10.1038/s41577-018-0044-0. View

12.

Elahi S, Weiss R, Merani S . Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. AIDS. 2015; 30(2):171-83. DOI: 10.1097/QAD.0000000000000917. View

13.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

14.

Shin H, Blackburn S, Intlekofer A, Kao C, Angelosanto J, Reiner S . A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity. 2009; 31(2):309-20. PMC: 2747257. DOI: 10.1016/j.immuni.2009.06.019. View

15.

Zhou Q, Munger M, Veenstra R, Weigel B, Hirashima M, Munn D . Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011; 117(17):4501-10. PMC: 3099570. DOI: 10.1182/blood-2010-10-310425. View

16.

Elahi S, Horton H . Association of HLA-alleles with the immune regulation of chronic viral infections. Int J Biochem Cell Biol. 2012; 44(8):1361-5. PMC: 3380151. DOI: 10.1016/j.biocel.2012.05.003. View

17.

Chen H, Wu Y, Chou F, Wu Y, Yeh L, Lin K . Intracellular Galectin-9 Enhances Proximal TCR Signaling and Potentiates Autoimmune Diseases. J Immunol. 2020; 204(5):1158-1172. DOI: 10.4049/jimmunol.1901114. View

18.

Tashiro H, Brenner M . Immunotherapy against cancer-related viruses. Cell Res. 2016; 27(1):59-73. PMC: 5223233. DOI: 10.1038/cr.2016.153. View

19.

Elahi S, Shahbaz S, Houston S . Selective Upregulation of CTLA-4 on CD8+ T Cells Restricted by HLA-B*35Px Renders them to an Exhausted Phenotype in HIV-1 infection. PLoS Pathog. 2020; 16(8):e1008696. PMC: 7410205. DOI: 10.1371/journal.ppat.1008696. View

20.

Motamedi M, Shahbaz S, Fu L, Dunsmore G, Xu L, Harrington R . Galectin-9 Expression Defines a Subpopulation of NK Cells with Impaired Cytotoxic Effector Molecules but Enhanced IFN-γ Production, Dichotomous to TIGIT, in HIV-1 Infection. Immunohorizons. 2019; 3(11):531-546. DOI: 10.4049/immunohorizons.1900087. View